Special Feature

User Panel

My Panel

My Panel

Bookmark Science Articles

Recent News
Bookmark / Share This Science Site

Diagnostic utility of interleukin-6 (IL-6) for primary bile duct cancer and changes in serum IL-6 levels following photodynamic therapy.

Diagnostic utility of interleukin-6 (IL-6) for primary bile duct cancer and changes in serum IL-6 levels following photodynamic therapy. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

  • Abstract Text of This Paper
  • Journal Published
  • MeSH Keywords of This Abstract
  • Chemicals and Substances Used in this Paper
  • Grants and Granting Agency of this Research
  • Database Accession Numbers Used in this Paper
  • Related Papers
  • Related Research Tags
  • Rate this Research Paper
  • Diagnostic utility of interleukin-6 (IL-6) for primary bile duct cancer and changes in serum IL-6 levels following photodynamic therapy. Abstract Text:

    justin l mottJustin L Mott,gregory j goresGregory J Gores,

    OBJECTIVES: Difficult diagnoses and a lack of effective therapy complicate biliary tract malignancies. Interleukin-6 (IL-6) is a human bile duct epithelium growth factor correlated with tumor burden. We evaluated the usefulness of serum IL-6 in the diagnosis of primary BDC and measured changes in serum IL-6 levels following photodynamic therapy (PDT). METHODS: We prospectively measured serum IL-6 levels in patients with BDC (N = 26: 14 patients treated with PDT, 12 with biliary drainage alone), hepatocelluar carcinoma (HCC, N = 26), and healthy adults (N = 23). Serum IL-6 levels were measured by an enzyme-linked immunosorbent assay. Patients with clinical conditions known to increase IL-6 levels were excluded. RESULTS: IL-6 was detected in all patients with BDC and HCC, and in 6 of 23 healthy adults. Median and mean levels of IL-6 were higher in patients with BDC than in both other groups (P < 0.001). Using a 25.8 pg/mL cutoff, IL-6 provided a diagnostic sensitivity of 73% and a specificity of 92%; positive and negative predictive values were 83% and 87%, respectively. Serum levels of IL-6 were correlated with tumor burden in BDC patients. One month after treatment of BDC with PDT, the mean IL-6 level decreased significantly from 282.1 +/- 121.8 to 38.2 +/- 9.9 pg/mL (P= 0.008). CONCLUSIONS: Serum IL-6 concentration is a useful addition to the available tests for the differential diagnosis of BDC, and serves as a marker for monitoring the response to treatment of BDC with PDT.

    Diagnostic utility of interleukin-6 (IL-6) for primary bile duct cancer and changes in serum IL-6 levels following photodynamic therapy. Publishing Authors By Initials

    jl mottJL Mott,gj goresGJ Gores,

    For similar tumor burden research abstracts see: tumor burden research

    PUBMED ID PMID:

    MEDLINE DATE:

    Diagnostic utility of interleukin-6 (IL-6) for primary bile duct cancer and changes in serum IL-6 levels following photodynamic therapy. Journal Published:

    PUBLICATION TYPE: Journal Article

    Journal: The American journal of gastroenterology

    VOLUME: 102

    Page Numbers: 2164-70

    Journal Abbreviation: Am. J. Gastroenterol.

    ISSN: 0002-9270

    DAY: 7

    MONTH: 07

    YEAR: 2007

    Diagnostic utility of interleukin-6 (IL-6) for primary bile duct cancer and changes in serum IL-6 levels following photodynamic therapy. Information

    Number of References:

    LANGUAGE: eng

    NlmUniqueID: 421030

    Diagnostic utility of interleukin-6 (IL-6) for primary bile duct cancer and changes in serum IL-6 levels following photodynamic therapy. Keywords Mesh Terms:

    KEYWORDS: Tumor Burden

    MESH TERMS: physiology

    Chemical & Substance for Abstract: Diagnostic utility of interleukin-6 (IL-6) for primary bile duct cancer and changes in serum IL-6 levels following photodynamic therapy. Information

    Substance Name: Interleukin-6

    Registry Number: 0

    Grant and Affiliation Information for Diagnostic utility of interleukin-6 (IL-6) for primary bile duct cancer and changes in serum IL-6 levels following photodynamic therapy.

    AFFILIATION: Institute for Digestive Research and Digestive Disease Center, Soon Chun Hyang University College of Medicine, Seoul, Korea.

    Country: United States

    United States Research PublicationUnited States Research Publication

    AGENCY:

    GRANT:

    ACRONYM:

    MEDLINETA: Am J Gastroenterol

    REFSOURCE: Am J Gastroenterol. 2007 Oct;102(10):217

    DATABASENAME:

    ACCESSION NUMBER:

    Number Hits: 0

    Diagnostic utility of interleukin-6 IL-6 for primary bile duct cancer and changes in serum IL-6 levels following photodynamic therapy Related Publications

     

    Molecular Station USER Menu

    Welcome to Molecular Station!

    You have to register before you can post on our forums or use our advanced features. Register Now! Its Free and Fast!

    Already registered? Login now below.

    User Name:

    Password:

    Already registered and Forgot your password? Click below to recover it.

    Recover Lost Password

    Join now - it's fast and free!

    Molecular Station is THE largest network of researchers, scientists and science lovers anywhere!

    Research Terms of Usage and Disclaimer
    Home
    Features

    Protocols

    DNA Forum

    Science Forum

    DNA Forum
    Biology Forum

    Science News


    [CaRP] XML error: Invalid document end at line 2

    For more click here:Science News